Product Description: BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively.
Applications: COVID-19-anti-virus
Formula: C14H24Cl2N4O2
References: [1]Kennedy TL, et al. BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle. Am J Pathol. 2016 Dec;186(12):3246-3260/[2]Salah H, et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med. 2016 Aug 3;8(350):350ra10/[3]Sapra G, et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun. 2014 Dec 9;5:5705/[4]Literati-Nagy B, et al. Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies. Metab Syndr Relat Disord. 2014 Mar;12(2):125-31/[5]Sarszegi Z, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37/[6]Szabados E, et al. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol. 2000 Apr 15;59(8):937-45.
CAS Number: 66611-37-8
Molecular Weight: 351.27
Compound Purity: 98.0
Research Area: Cardiovascular Disease; Cancer
Solubility: DMSO : 11.33 mg/mL (ultrasonic;warming)/H2O : 100 mg/mL (ultrasonic)
Target: PARP
English
Deutsch
